Statins and dementia: A genetic key to unlocking who benefits
A study emulating a clinical trial using UK Biobank data and causal machine learning has found that the overall effect of statin initiation on dementia risk is negligible. However, the research identified significant heterogeneity in treatment effects. A key finding is that individuals with a high genetic risk for Alzheimer’s disease, specifically a high polygenic risk score that excludes the APOE gene, showed a cognitive benefit from statin use, with a reduced risk of both all-cause dementia and Alzheimer’s disease.
Why it might matter to you:
This research moves beyond a one-size-fits-all approach to prevention, highlighting how genetic profiling could refine strategies for reducing dementia risk in aging populations. For professionals focused on chronic disease and behavioral prevention, it underscores the potential for integrating genetic data to personalize and enhance the efficacy of pharmacological interventions, shifting the focus towards more targeted, risk-stratified care plans.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
